Drug intelligence / Profile preview

YSTSLX

Development stage: Preclinical
Lead developer: Jiangsu Coast Pharmaceutical
Modality: Small Molecules

Overview

YSTSLX is an antibacterial drug candidate currently under development by Jiangsu Coast Pharmaceutical, a subsidiary of Yangtze River Pharmaceutical Group. The drug is specifically being investigated for the treatment of bacterial peritonitis. While the exact chemical identity and mechanism of action are not publicly disclosed in the available pipeline information, it is categorized within the company's antibacterial and anti-infective research portfolio. The code name YSTSLX likely follows the developer's internal pinyin-based naming convention for pipeline products.

Other names: 细菌性腹膜炎

Beyond the preview

Go deeper on YSTSLX.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YSTSLX.

Explore the full profile